Physician profile
David J Freestone
NPI 1801861851
$1,420.39
in general payments reported to CMS, 2019-2025
28 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $62.81 · 2022: $38.35 · 2023: $336 · 2024: $211 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $152.45 | 2019-2023 | Rotateq, Vaxelis, Gardasil 9 |
| Novo Nordisk INC | $152.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $130.70 | 2019-2025 | |
| Amgen INC. | $110.73 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $74.11 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $70.01 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.74 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $65.13 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $64.26 | 2019-2025 | Spravato |
| Organon LLC | $55.47 | 2023-2025 | Nexplanon, Nuvaring |
| Sanofi-Aventis U.S. LLC | $48.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.48 | 2019-2020 | |
| Astellas Pharma US INC | $32.76 | 2020-2024 | Veozah |
| Lilly USA, LLC | $31.50 | 2019-2025 | Zepbound, Mounjaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.53 | 2019-2025 | Farxiga |
| Mylan Specialty L.P. | $29.73 | 2019 | |
| Alkermes, INC. | $26.85 | 2023 | Aristada, Lybalvi |
| Intuitive Surgical, INC. | $26.35 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $24.90 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $24.36 | 2019 | |
| Esperion Therapeutics, INC. | $19.16 | 2025 | Nexletol |
| Neurelis, INC. | $16.82 | 2025 | Valtoco |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.78 | 2023 | |
| Exact Sciences Corporation | $16.66 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $16.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.15 | 2020 | |
| Medtronic, INC. | $13.10 | 2023 | Inpen Smart Insulin Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Freestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.